Welcome to our dedicated page for RenovoRx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on RenovoRx stock.
RenovoRx, Inc. (RNXT) is a medical device and biopharmaceutical company based in Silicon Valley, California. The company focuses on developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents to specific locations in the peripheral vascular system. With FDA clearance for their flagship product, RenovoCath™ RC120, RenovoRx is introducing this cutting-edge technology to the clinical market.
RenovoRx's proprietary platform, Trans-Arterial Micro-Perfusion (TAMP), aims to revolutionize cancer treatment by ensuring precise therapeutic delivery directly to the tumor site. This targeted approach is designed to reduce the toxicities commonly associated with systemic intravenous therapy, potentially improving therapeutic outcomes for cancer patients.
The company is driven by a highly motivated team with extensive experience in the medical field and supported by a robust medical advisory board and a distinguished board of directors. RenovoRx's commitment to innovation and patient care has positioned it as a leader in the area of targeted therapeutic delivery.
For more information or inquiries, please contact RenovoRx at info@renovorx.com.
Rhea-AI Summary
RenovoRx promotes Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer, showcasing commitment to leadership and innovation in precision oncology therapies. Ms. Gentry's new role will focus on clinical operations for RenovoGemTM in Locally Advanced Pancreatic Cancer, while Mr. Kocak will lead financial management and strategic planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
-
Rhea-AI Summary
RenovoRx, Inc. (RNXT) provided a letter to shareholders from CEO Shaun Bagai, highlighting key achievements in 2023 and the company's focus on advancing the development of their proprietary targeted combination therapy platform, Trans-Arterial Micro-Perfusion (TAMP™). The completion of a $6.1 million private placement has extended their cash runway, allowing them to drive towards a second interim analysis for their pivotal Phase III TIGeR-PaC study in late 2024. The study involves their lead product candidate, RenovoGem™, for the treatment of LAPC, utilizing their TAMP administration technology combined with the FDA-approved cancer drug, gemcitabine. RenovoRx also announced a collaboration with Imugene to explore expansion of their TAMP product pipeline with Imugene’s CF33 oncolytic virus therapy for the treatment of difficult-to-access tumors. Additionally, the company filed an additional international patent application under the Patent Cooperation Treaty for their TAMP therapy platform, further bolstering their intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
-
Rhea-AI Summary
RenovoRx, Inc. has announced the closing of a private placement, resulting in gross proceeds of approximately $6.1 million. The company's management team and Board of Directors participated in the private placement, reflecting their strong belief in the company. The funds will extend RenovoRx’s cash runway as it continues its ongoing pivotal TIGeR-PaC Phase III clinical trial, with a second interim analysis expected in late 2024. The company also plans to use the proceeds to engage additional clinical trial sites for its Phase III CouGar study in bile duct cancer and explore other potential pipeline indication opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.24%
Tags
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) announced the expansion of their clinical development pipeline in preparation for the commencement of the CouGar Trial, a second Phase III trial evaluating RenovoGem in bile duct cancer. The trial aims to evaluate the safety and efficacy of intravenous chemotherapy versus Trans-Arterial Micro-Perfusion via RenovoGem with intravenous durvalumab for unresectable, locally advanced eCCA. The study brings hope for a new treatment option for patients diagnosed with this aggressive cancer, addressing the urgent clinical need for a safe and effective therapy in this important patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.72%
Tags
-
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) announces positive research supporting RenovoGem™ and TAMP™ therapy platform for Locally Advanced Pancreatic Cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
-
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) has filed an international patent application for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, expanding its IP coverage for delivering therapeutic classes across DNA/RNA altering modalities, cell therapy, and antibody-based therapies. The company holds 9 issued patents and 9 pending patents for its TAMP platform and delivery system in the US, EU, and Asia. The new patent application aims to provide a novel and important pathway for targeted delivery of therapeutic classes, with the potential to open up new market potential and expand the upside value proposition of TAMP commercially. RenovoRx is currently investigating TAMP in its Phase III TIGeR-PaC clinical trial for the treatment of Locally Advanced Pancreatic Cancer (LAPC) following stereotactic body radiation therapy (SBRT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.35%
Tags
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) appoints Dr. Michel Ducreux, a renowned oncologist, to its Scientific Advisory Board. Dr. Ducreux brings extensive experience in gastrointestinal oncology and research, and is expected to contribute to the advancement of the Company's novel clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.86%
Tags
-
Rhea-AI Summary
RNXT - RenovoRx Announces Financial Results and Collaboration with Imugene for TAMP Platform Expansion. The company remains focused on advancing its Phase III TIGeR-PaC clinical trial for the treatment of LAPC. Collaboration with Imugene further validates the TAMP platform and will expand use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy. Financial results for the third quarter ended September 30, 2023, show a cash position of $3.2 million, increased R&D expenses, flat G&A expenses, a net loss of $1.4 million, and 10,693,080 outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.38%
Tags
-
Rhea-AI Summary
RenovoRx CEO Shaun Bagai to present at ROTH MKM Healthcare Opportunities Conference on October 12, 2023. Bagai will discuss recent milestones including research collaboration with Imugene and highlights from Phase III TIGeR-PaC study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.92%
Tags
Rhea-AI Summary
RenovoRx announces positive Phase III TIGeR-PaC interim study results, collaboration with Imugene, and financial results for Q2 2023. The study shows an 8-month delay in cancer progression, 6-month overall survival benefit, and 65% reduction in adverse effects. The collaboration aims to explore oncolytic virus therapy using RenovoRx's TAMP platform. Q2 financial results show $6.0 million in cash and cash equivalents, $1.9 million in R&D expenses, and $1.4 million in G&A expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
FAQ
What is the current stock price of RenovoRx (RNXT)?
The current stock price of RenovoRx (RNXT) is $1.2101 as of November 21, 2024.
What is the market cap of RenovoRx (RNXT)?
The market cap of RenovoRx (RNXT) is approximately 26.9M.
What does RenovoRx, Inc. specialize in?
RenovoRx specializes in developing targeted delivery solutions for fluids, including diagnostic and therapeutic agents, in the peripheral vascular system.
What is the RenovoCath™ RC120?
RenovoCath™ RC120 is a medical device developed by RenovoRx for targeted therapeutic delivery. It has received FDA clearance.
What is the Trans-Arterial Micro-Perfusion (TAMP) platform?
The TAMP platform is RenovoRx's patented technology designed for precise therapeutic delivery directly to tumor sites, potentially reducing toxicities associated with systemic therapies.
Where is RenovoRx headquartered?
RenovoRx is headquartered in Silicon Valley, California.
Who backs RenovoRx's initiatives?
RenovoRx is backed by a broad medical advisory board and a strong board of directors.
What is the primary goal of RenovoRx's therapies?
The primary goal is to improve therapeutic outcomes for cancer patients by directly targeting tumors and minimizing treatment toxicities.
How can I contact RenovoRx for more information?
You can contact RenovoRx via email at info@renovorx.com.
What makes RenovoRx's technology unique?
Their technology ensures high-concentration delivery of therapeutic agents to specific vasculature without perfusion overlap to other regions, enhancing treatment efficacy and safety.
Is RenovoRx currently in clinical stages?
Yes, RenovoRx is a clinical-stage biopharmaceutical company.
What recent achievements has RenovoRx made?
RenovoRx has received FDA clearance for RenovoCath™ RC120 and is actively introducing its innovative technology to the clinical market.
RenovoRx, Inc.
Nasdaq:RNXT
RNXT Rankings
RNXT Stock Data
26.88M
23.54M
1.9%
8.18%
0.3%
Biotechnology
Pharmaceutical Preparations
United States of America
SAN JOSE